Ortner MJ. Genomics 2000: Drug Development in the Post-Genomic Era

Southborough, MA - With the imminent sequencing of the human genome will come the challenge of what to do with this mind-boggling piece of information—a task that is already being met in the sciences of population genetics, functional genomics, proteomics and pharmacogenomics.

Genomics 2000 is a sequel to the best-selling first edition, Genomics and Human Therapeutics Development. Focusing on the post-genomic era, this report is aimed at the business and science professional alike with a balanced attention to both the business and the scientific aspects of genomics-based sciences and the new world facing the pharmaceutical industry.

There are now serious questions to be answered:

• Where are he genes located and what does each one do?


• How are they regulated?


• How are gene expression, protein synthesis and post-translation events coordinated?


• How do each gene’s protein products interact with one another?


• How do single nucleotide polymorphisms (SNPs) affect health and disease?


• How are diseases linked to genetics both in monogenic and polygenic disorders?


• How can diseases be predicted in populations or individuals based on gene sequences?


• How can medicines be designed to act optimally with an individual’s genetic makeup?


• Is antisense therapy a viable medication?


• What is the future of gene therapy: can we replace defective genes safely and effectively? Will this be a final cure for everything?

Genomics 2000 describes the latest techniques involved in genome sequencing, gene identification, gene expression analysis, SNPs, and bioinformatics. This report will help the reader to grasp the realities of genomic and related research and also to gain insight into the enormous challenges ahead, especially for the pharmaceutical industry.

D&MD’s Genomics 2000: Drug Development in the Post-Genomics Era Report by Mary J. Ortner, Ph.D., will provide you with the tools you need to compete in this market.